

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Applicants:</b>	Ernest J. Lee, et al.	<b>Examiner:</b>	Schlientz, Nathan
<b>Serial No.:</b>	10/626,275	<b>Art Unit:</b>	1616
<b>Filed:</b>	July 24, 2003	<b>Atty Docket:</b>	PC28017
<b>Title:</b>	PRAMIPEXOLE ONCE-DAILY DOSAGE FORM		

**RESPONSE**

This communication is in response to the final Office Action dated July 23, 2010, setting forth a three (3) month period for reply. A Petition and payment for a two (2) month Extension of Time is intended to be filed herewith, making this response due by December 23, 2010. In the event such request does not accompany this paper, applicants hereby request such extension and authorize the office to charge account no. 16-1445 the required fee.

**Status of Claims**

Claims 1, 3-10, 12-15, 20 and 24-41 are pending, with method claims 26-27 withdrawn from consideration as being directed to a non-elected invention. Applicants respectfully request rejoinder of these method claims under the USPTO's Rejoinder Practice (MPEP § 821.04) in the event that the product (composition) claims are found to be allowable.

**Claim Rejections Under 35 USC § 112, 2<sup>nd</sup> Paragraph**

Claims 1, 3-10, 12-15, 20, 24-25 and 28-41 stand rejected under 35 USC § 112, 2<sup>nd</sup> Paragraph. The Examiner maintains that the use of the term "about" in phrases such as "no more than about", "greater than about", "at least about" and "not greater than about", as well as the use of the term "substantially" in "not substantially greater", render these claims indefinite.

Applicants respectfully traverse.

**Usage in the Instant Application**

All the noted usages of the term "about" and "substantially" relate to the test results obtained upon the in vitro and/or in vivo evaluation of the pharmacokinetic profile of the sustained